We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Amgen Fears 'Staggering Loss' After FDA Exclusivity Denial

Law360 (February 23, 2018, 8:06 PM EST) -- Amgen Inc. urged the D.C. Circuit on Friday to quickly block generic versions of its lucrative calcium-control drug Sensipar, saying it faces a “staggering loss” of sales because the U.S. Food and...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only

Court

Appellate - DC Circuit

Nature of Suit

2890 Other Statutory Actions

Date Filed

February 21, 2018

Law Firms

Companies

Government Agencies

Judge Analytics

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.